Targeted antibacterials based on endolysin and phage technology.
| Date | Round | Amount |
|---|---|---|
| Oct 2022 | Growth Dutch/Swiss biotech Micreos secured EUR25M in growth funding for its Gladskin skincare brand and pharmaceutical endolysin programmes. | $25M |
| Oct 2021 | Funding round Dutch biotech Micreos raised EUR 32M to develop its endolysin platform aimed at replacing antibiotics. | $37.8M |